Literature DB >> 9774252

Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost.

L H Clapp1, S Turcato, S Hall, M Baloch.   

Abstract

The role of K+ channels in mediating vasorelaxation induced by two prostacyclin analogues was investigated in guinea-pig aorta. Iloprost caused substantial relaxation of tissues contracted with phenylephrine or 25 mM K+ but not 60 mM K+. In endothelial-denuded tissues, maximal relaxations to iloprost, cicaprost or isoprenaline were inhibited by approximately 40-50% with tetraethylammonium or iberiotoxin, both blockers of large conductance Ca2+-activated K+ (BKCa) channels. In contrast, the response to forskolin, an activator of adenylate cyclase was marginally inhibited by tetraethylammonium. The K(ATP) channel blocker, glibenclamide significantly augmented the response to iloprost but not cicaprost. These effects were largely inhibited by the EP1 receptor antagonist, 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid 2-[1-oxo-3(4-pyridinyl)propyl]hydrazide, monohydrochloride (SC-51089) and partially by indomethacin, suggesting that iloprost relaxation is counterbalanced by activation of EP1 receptors, in part through a constrictor prostaglandin. We conclude that BKCa channels play an important role in mediating the effects of iloprost and cicaprost and raises the possibility that cyclic AMP-independent pathways might be involved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774252     DOI: 10.1016/s0014-2999(98)00549-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  cAMP-independent relaxation of smooth muscle cells via Gs-coupled receptors.

Authors:  Stephan L Peters; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11       Impact factor: 3.000

Review 2.  Calcium-activated potassium channels and endothelial dysfunction: therapeutic options?

Authors:  Michel Félétou
Journal:  Br J Pharmacol       Date:  2009-01-29       Impact factor: 8.739

3.  Effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cyclic AMP elevation in isolated guinea-pig aorta.

Authors:  S Turcato; L H Clapp
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

4.  A role for cyclooxygenase in aging-related changes of beta-adrenoceptor-mediated relaxation in rat aortas.

Authors:  Khong Bee Kang; M A Sharmini Rajanayagam; Andrea van der Zypp; Henryk Majewski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-04-03       Impact factor: 3.000

5.  Endothelium modulates vasoconstrictor response to prostaglandin I2 in rat mesenteric resistance arteries: interaction between EP1 and TP receptors.

Authors:  F E Xavier; J Blanco-Rivero; M Ferrer; G Balfagón
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

6.  Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs.

Authors:  Ralph T Schermuly; Soni S Pullamsetti; Susanne C Breitenbach; Norbert Weissmann; Hossein A Ghofrani; Friedrich Grimminger; Sigrid M Nilius; Karsten Schrör; Jutta M Kirchrath; Werner Seeger; Frank Rose
Journal:  Respir Res       Date:  2007-01-26

Review 7.  Hypoxic pulmonary vasoconstriction: role of voltage-gated potassium channels.

Authors:  M Sweeney; J X Yuan
Journal:  Respir Res       Date:  2000-07-03

8.  Vasorelaxant-Mediated Antihypertensive Effect of the Leaf Aqueous Extract from Stephania abyssinica (Dillon & A. Rich) Walp (Menispermaceae) in Rat.

Authors:  Chamberlin Fodem; Elvine Pami Nguelefack-Mbuyo; Magloire Kanyou Ndjenda Ii; Albert Kamanyi; Télesphore Benoit Nguelefack
Journal:  Biomed Res Int       Date:  2021-10-08       Impact factor: 3.411

Review 9.  Revisiting the Large-Conductance Calcium-Activated Potassium (BKCa) Channels in the Pulmonary Circulation.

Authors:  Divya Guntur; Horst Olschewski; Péter Enyedi; Réka Csáki; Andrea Olschewski; Chandran Nagaraj
Journal:  Biomolecules       Date:  2021-11-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.